prostate cancer Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Languages supported at study center
Age Group

Male only (41)
Female only (2)
Any (10)

Phase 0 (1)
Phase 1 (10)
Phase 1/2 (6)
Phase 2 (9)
Phase 3 (4)
Unknown (22)

Interventional (40)
Observational (8)
INTERVENTIONAL (1)

Radboud University (4)
Martini-Klinik am UKE GmbH (2)
Shenzhen Geno-Immune Medical Institute (2)
University of Washington (2)
Washington University School of Medicine (2)
Weill Medical College of Cornell University (2)
Adcentrx Therapeutics (1)
Amgen (1)
Andrei Iagaru (1)
Arcus Biosciences, Inc. (1)
AstraZeneca (1)
Bayer (1)
BioNTech RNA Pharmaceuticals GmbH (1)
Brown University (1)
Celgene (1)
Centre Hospitalier Universitaire de Pointe-a-Pitre (1)
Chinese University of Hong Kong (1)
Dana-Farber Cancer Institute (1)
ESSA Pharmaceuticals (1)
Exelixis (1)
Grupo de Investigación Clínica en Oncología Radioterapia (1)
Hoffmann-La Roche (1)
Jonsson Comprehensive Cancer Center (1)
Luis Souhami (1)
Metro Health, Michigan (1)
Myriad Genetic Laboratories, Inc. (1)
Nanospectra Biosciences, Inc. (1)
Poseida Therapeutics, Inc. (1)
Reykjavik University (1)
Rutgers, The State University of New Jersey (1)
Sanofi Pasteur, a Sanofi Company (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Stony Brook University (1)
Sunnybrook Health Sciences Centre (1)
Turku University Hospital (1)
Universitaire Ziekenhuizen Leuven (1)
University of Miami (1)
University of Pennsylvania (1)
University of Virginia (1)
VA Greater Los Angeles Healthcare System (1)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)

No (48)
Yes (5)

No (53)

All Languages (1)
Argentinian Spanish (1)
Australian English (1)

Adult (18+) (52)
Pediatric (Under 18) (8)

I am/have/had

I am/have/hadcancer

I am/have/hadprostatectomy

I am/have/hadadenocarcinoma of prostate

I am/have/hadandrogen suppression

I am/have/hadadenocarcinoma

I am/have/hadprostate specific antigen

I am/have/hadbone scan

I am/have/hadcastration-resistant prostate cancer

I am/have/hadorchiectomy

I am/have/hadmetastatic prostate cancer

I am/have/hadprostate cancer metastatic

I am/have/hadmetastasis

I am/have/hadbiopsy of prostate

I am/have/hadprogressive disease

I am/have/hadserum testosterone

I am/have/hadbrachytherapy

I am/have/hadtransrectal ultrasound

I am/have/hadexternal beam radiation therapy

I am/have/hadsoft tissue disease

I am/have/hadprostate carcinoma

added new label for I am/have/had

I am looking for

I am looking forandrogens

I am looking forantiandrogen therapy

I am looking fortestosterone

I am looking forgonadorelin

I am looking forhormone therapy

I am looking forendocrine therapy

I am looking forantiandrogens

I am looking forbicalutamide

I am looking fordocetaxel

I am looking forabiraterone

I am looking forluteinizing hormone-releasing hormone agonist

I am looking forenzalutamide

I am looking forgoserelin

I am looking forprednisone

I am looking forluteinizing hormone

I am looking fordiphosphonates

I am looking forcabazitaxel

I am looking forapalutamide

I am looking forhbed-cc

I am looking forgonadotropin

added new label for I am looking for

Advanced Filters

Found 52 clinical trials

Marker Driven Selection of Patients for Prostate Biopsy and Management

The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood biomarkers is more effective at detecting prostate cancer than standard of care interpretation of mpMRI with the Prostate Imaging …

multiparametric magnetic resonance imaging

testosterone

digital rectal examination

biopsy of prostate

tumor markers

0 views
19 Feb, 2024

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death.

castration-resistant prostate cancer

dna damage

prostate specific antigen

metastasis

prostate-specific antigen

0 views
19 Feb, 2024